Northfield Laboratories Inc. lost $6.1million, or 23 cents a share, as compared to a year-ago quarter's loss of $6.4 million, or 24 cents a share. Northfield is re-analyzing its Phase III trial for its blood substitute product known as PolyHeme.
Monday, April 09, 2007
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment